Gescuk Bryan D, Davis John C
Division of Rheumatology, University of California, San Francisco 94143, USA.
Curr Opin Rheumatol. 2002 Sep;14(5):515-21. doi: 10.1097/00002281-200209000-00006.
The last significant breakthrough in the treatment of systemic lupus erythematosus (SLE) was the use of cyclophosphamide and methylprednisolone in the treatment of lupus nephritis. Recent advances in immunology, oncology, and endocrinology have resulted in many potential therapies for SLE. These therapies include new immunosuppressants, biologic medications, tolerizing agents, immunoablation techniques, and hormonal medications. Each of these approaches will be discussed in this review. Some therapies are currently in use in clinical rheumatology practice (mycophenolate mofetil) and others are entering phase I trials (anti-BLyS monoclonal antibody). While some of these new therapies target specific inflammatory mechanisms in SLE (anti-CD40L monoclonal antibody), others work by nonspecific inhibition of the immune system (immunoablation).
系统性红斑狼疮（SLE）治疗方面的最后一项重大突破是使用环磷酰胺和甲泼尼龙治疗狼疮性肾炎。免疫学、肿瘤学和内分泌学的最新进展带来了许多针对SLE的潜在治疗方法。这些治疗方法包括新型免疫抑制剂、生物药物、免疫耐受剂、免疫消融技术和激素药物。本综述将讨论上述每种方法。有些治疗方法目前已应用于临床风湿病实践（霉酚酸酯），其他一些则正在进入I期试验（抗BLyS单克隆抗体）。虽然这些新疗法中的一些针对SLE中的特定炎症机制（抗CD40L单克隆抗体），但其他疗法则通过非特异性抑制免疫系统起作用（免疫消融）。
